Andrew Wagner

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint Treatment of advanced soft tissue sarcoma: conventional agents and promising new drugs
    Andrew Wagner
    Harvard Medical School, Department of Medical Oncology and Ludwig Center for Cancer Research, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Natl Compr Canc Netw 5:401-10. 2007
  2. doi request reprint Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial
    Andrew J Wagner
    Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 118:5894-902. 2012

Detail Information

Publications2

  1. ncbi request reprint Treatment of advanced soft tissue sarcoma: conventional agents and promising new drugs
    Andrew Wagner
    Harvard Medical School, Department of Medical Oncology and Ludwig Center for Cancer Research, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Natl Compr Canc Netw 5:401-10. 2007
    ..As more underlying genetic mechanisms are uncovered, new agents designed to target these lesions will lead to more specific, less toxic, and more effective therapies...
  2. doi request reprint Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial
    Andrew J Wagner
    Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 118:5894-902. 2012
    ..This study assessed the activity of tivantinib (ARQ 197), a selective MET inhibitor, in patients with MiT-associated tumors...